MK-767. Kyorin/Banyu/Merck.
MK-767 (KRP-297, L-410198) is a peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma agonist under development by Banyu, Kyorin and Merck for the potential treatment of diabetes. The compound is currently undergoing phase III trials in the US and phase I trials in Japan.
Calkin
Anna C
AC
Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, St Kilda Rd Central, Melbourne, Victoria 8008, Australia. anna.calkin@baker.edu.au
Thomas
Merlin C
MC
Cooper
Mark E
ME
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013844:Thiazoles / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D053778:Thiazolidines
D007004:Hypoglycemic Agents; D013844:Thiazoles; D053778:Thiazolidines; C116017:5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide